Bridging the Gap in TKI-Resistant NSCLC: The Strategic Rise of Antibody-Drug Conjugates (ADCs) Introduction The treatment landscape for Non-Small Cell Lung Cancer (NSCLC) has been revolutionized by EGFR Tyrosine Kinase Inhibitors (TKIs). However, the inevitable development of acquired resistance limits their long-term efficacy. To bridge this therapeutic gap, Antibody-Drug Conjugates (ADCs) have emerged as a …
Yeast surface display has emerged as a powerful and versatile technology for antibody discovery and protein engineering, playing a critical role in therapeutic development. By leveraging the eukaryotic machinery of yeast, this platform ensures proper protein folding and display, enabling the isolation of high-affinity binders through robust library screening. Technology Overview (i) Display Mechanism The …
Protein-protein interactions (PPIs) govern cellular communication and are prime targets for therapeutic intervention. Peptide library screening has emerged as a powerful, high-throughput strategy to dissect these interactions with precision. By systematically displaying thousands of peptide sequences, researchers can map binding epitopes, identify lead compounds, and optimize candidates efficiently. This article outlines the core strategies, technical …